How could the pursuit of FDA approval for VDPHL01 affect the Center for Drug Evaluation and Research?
The Center for Drug Evaluation and Research must review VDPHL01's application for hair loss treatment. The submission of the New Drug Application for VDPHL01 requires the Center for Drug Evaluation and Research to initiate a comprehensive review. This review will assess the drug's efficacy and safety profile, particularly its status as an extended-release minoxidil formulation. The Center will evaluate the positive phase 3 data, which showed 78.8% of patients reported improvements in hair coverage on the Androgenetic Alopecia Impact Rating Scale, compared to 35.3% in the placebo group. This evaluation is critical as the drug aims to be the first oral minoxidil approved and an alternative to finasteride.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Gone quiet
How it reaches Center for Drug Evaluation and Research
-
Veradermics, Incorporated is seeking approval from the FDA for its lead therapy, VDPHL01, which targets hair loss. The company recently released positive Phase 3 trial results for VDPHL01, an extended-release minoxidil formulation. In the study, 78.8% of patients on the daily dose and 85% on the twice-daily dose reported improvements in hair coverage compared to 35.3% in the placebo group.
The full event1independent outlet -
The filing of the New Drug Application for VDPHL01 with the Food and Drug Administration requires the Center for Drug Evaluation and Research to formally begin the evaluation. This process involves scrutinizing the drug's clinical data, such as the positive phase 3 results, to determine its viability for market approval.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Drug Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- VDPHL01 is an extended-release minoxidil formulation for pattern hair loss.fool.com
- 78.8% of patients on the daily dose reported improvements in hair coverage on the AAIRS.fool.com
- The drug met all primary and secondary endpoints in the phase 3 study.fool.com
- VDPHL01 would be the first oral minoxidil approved.fool.com
Why it matters
The Center for Drug Evaluation and Research plays a crucial role in maintaining public health standards by rigorously vetting novel therapies. A successful review of VDPHL01 would represent a significant regulatory milestone, as it would approve the first oral minoxidil, a class of drug that has been absent from FDA approval for nearly three decades.
This review is also important given the market size of the condition. Pattern hair loss affects an estimated 50 million men and 30 million women in the U.S., representing a market worth more than $30 billion by 2028. The Center's decision directly impacts the availability of a non-hormonal alternative to finasteride for millions of patients.
What we don't know yet
- Will the Center for Drug Evaluation and Research grant fast-track status to VDPHL01 given its potential to address an unmet medical need?
- What specific safety data will the Center prioritize during its review of the extended-release gel matrix formulation?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comOct 25
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.